Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTLNASDAQ:BNTCOTCMKTS:MATNNYSEAMERICAN:NTNOTCMKTS:QBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$10.80-2.1%$6.68$4.92▼$25.58$5.50M1.34136,759 shs91,305 shsBNTCBenitec Biopharma$13.14+3.1%$14.27$7.05▼$17.15$345.71M0.3755,949 shs74,946 shsMATNMateon Therapeutics$0.05$0.06$0.13▼$0.38$4.12M1.33338,444 shs15,461 shsNTNNTN Buzztime$2.00+1.0%$0.83$0.94▼$7.76$5.95M0.721.63 million shs29,428 shsQBIOQ Biomed$0.00$0.00▼$0.03N/A2.198,584 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%+56.22%+63.47%+96.07%+32.29%BNTCBenitec Biopharma0.00%+15.77%-15.12%+6.66%+48.64%MATNMateon Therapeutics0.00%+4.73%-23.98%-20.12%+54.52%NTNNTN Buzztime+8.70%+5.26%+1,012.35%+957.64%+4.19%QBIOQ Biomed0.00%0.00%0.00%-50.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.9798 of 5 stars3.65.00.00.02.40.00.6BNTCBenitec Biopharma2.0176 of 5 stars3.62.00.00.02.50.80.0MATNMateon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.20Buy$33.00205.70% UpsideBNTCBenitec Biopharma 3.22Buy$23.8381.38% UpsideMATNMateon Therapeutics 0.00N/AN/AN/ANTNNTN Buzztime 0.00N/AN/AN/AQBIOQ Biomed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTN, BNTC, MATN, QBIO, and ARTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.005/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.004/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/ABNTCBenitec Biopharma$80K4,311.56N/AN/A$4.68 per share2.81MATNMateon TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ANTNNTN Buzztime$19.81M0.30$0.46 per share4.38$1.76 per share1.14QBIOQ Biomed$280KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/AMATNMateon Therapeutics-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/ANTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/AQBIOQ Biomed-$2.05MN/A0.00N/AN/AN/AN/AN/AN/ALatest NTN, BNTC, MATN, QBIO, and ARTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.490.49BNTCBenitec Biopharma0.0114.8014.80MATNMateon TherapeuticsN/A0.170.17NTNNTN Buzztime3.300.950.95QBIOQ BiomedN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BNTCBenitec Biopharma52.19%MATNMateon Therapeutics0.07%NTNNTN Buzztime6.31%QBIOQ BiomedN/AInsider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%BNTCBenitec Biopharma1.30%MATNMateon Therapeutics39.22%NTNNTN Buzztime24.20%QBIOQ Biomed28.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5550,000542,000Not OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataMATNMateon Therapeutics1390.24 millionN/ANot OptionableNTNNTN Buzztime192.98 millionN/ANot OptionableQBIOQ Biomed3N/AN/ANot OptionableNTN, BNTC, MATN, QBIO, and ARTL HeadlinesRecent News About These CompaniesQ BioMed IncApril 8, 2025 | uk.investing.comOrchestra Biomed Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comOrchestra BioMed Reports Q3 2024 Results, Advances Key Clinical ProgramsNovember 14, 2024 | msn.comIBM's newest 156-qubit quantum chip can run 50 times faster than its predecessor — equipping it for scientific researchNovember 14, 2024 | msn.comFormer Bigfoot Biomedical CEO takes corner office at AI medtech company Q-BioOctober 11, 2024 | massdevice.comA Powerful New Tool for Biomedical ResearchSeptember 12, 2024 | msn.comOpinion: Artificial intelligence already improving biomedical research, health careSeptember 5, 2024 | sandiegouniontribune.comSClearmind Biomedical wins FDA clearance for Neuroblade minimally invasive neuroendoscopy techAugust 27, 2024 | massdevice.comMayo Clinic taps startup SandboxAQ to study new tech — quantum sensing and AI — for cardiac diagnosticsAugust 8, 2024 | fiercehealthcare.comF18th Annual Q-Bio Conference: Global scholars explore new Frontiers in quantitative biologyAugust 7, 2024 | eurekalert.orgEE&Q Master Cordless Gutta Percha Obturator from Meta BioMedMarch 24, 2024 | news-medical.netNClearside Biomedical Q4 2023 Earnings PreviewMarch 11, 2024 | msn.comQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesFebruary 24, 2024 | benzinga.comBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesFebruary 13, 2024 | msn.comBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthJanuary 28, 2024 | msn.comQ BioMed Inc QBIONovember 16, 2023 | morningstar.comMBiomedical Sciences PhD ProgramNovember 13, 2023 | uwyo.eduUQ&A: How generative AI could help accelerate biomedical researchNovember 6, 2023 | phys.orgPQBIO Q BioMed Inc.August 18, 2023 | seekingalpha.comQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in EuropeApril 17, 2023 | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTN, BNTC, MATN, QBIO, and ARTL Company DescriptionsArtelo Biosciences NASDAQ:ARTL$10.80 -0.24 (-2.13%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$10.80 0.00 (0.00%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Benitec Biopharma NASDAQ:BNTC$13.14 +0.40 (+3.14%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Mateon Therapeutics OTCMKTS:MATN$0.05 0.00 (0.00%) As of 07/3/2025Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.NTN Buzztime NYSEAMERICAN:NTN$2.00 +0.02 (+1.01%) As of 07/3/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.Q Biomed OTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
